# OnCo record sesen-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sesen-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sesen-bio" ;
  schema:name "Sesen Bio"@en ;
  schema:alternateName "Sesen Bio, Inc."@en, "Eleven Biotherapeutics, Inc."@en ;
  schema:description "Sesen Bio developed Vicineum, a targeted protein treatment put directly into the bladder for early bladder cancer that had stopped responding to BCG. The US regulator turned down its application in 2021, and in 2023 the company merged into Carisma Therapeutics."@en ;
  schema:url <https://onco.cc/companies/sesen-bio/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1485003/000148500323000090/sesn-20221231.htm>, <https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex99-1.htm>, <https://www.thirdrockventures.com/portfolio/sesen> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/epcam/> .